#Japan #Tokyo #radiopharmaceuticals #Nuclear Medicine #AMS Planning

AMS Planning Secures Significant Funding for Next-Level Nuclear Medicine

AMS Planning, Inc., a promising start-up in nuclear medicine based in Minato, Tokyo, has successfully raised 190 million yen in a pre-Series A funding round held on May 30, 2025. This funding round welcomed existing investor Mirai Sozo Investments, alongside Vision Incubate and other participants through a third-party allotment of shares. With this latest round, the company's total raised capital has reached approximately 300 million yen.

The capital is earmarked for various strategic initiatives, including the development of radiopharmaceuticals such as 68Ga-PSMA-11, the commercialization of radioisotope wastewater treatment systems, support for medical institutions both domestically and internationally, and enhanced recruitment of engineers, regulatory affairs specialists, and business development professionals.

About AMS Planning

Founded in February 2019 as a certified startup originating from Hokkaido University, AMS Planning aims to reshape the landscape of nuclear medicine with the motto, "Nuclear Reimagined for Advanced Cures." The company is committed to the social implementation of theranostics technology, merging diagnostics and therapeutics. With the rapidly evolving field of nuclear medicine, AMS strives to tackle fundamental challenges by innovating through its unique business model known as the "AMS Growth Flywheel," creating a positive cycle for both the company and society while advancing its theranostics and engineering solution businesses.

Key Business Areas

• - Theranostics Business (TD): AMS is driving the development and introduction of PET diagnostic drugs such as 68Ga-PSMA-11. Furthermore, it is in the planning stages for international clinical trials of new radioisotope therapies based on astatine-211.
• - Engineering Solutions Business (ES): This segment focuses on developing and providing systems for handling radioactive wastewater resulting from radiation ligand therapy, promoting efficiency and safety in the management of radioactive waste at medical institutions.

Through these efforts, AMS contributes to solving challenges in Japan's nuclear medicine sector and the realization of innovative healthcare solutions.

Objectives for the Funding

With this new funding, AMS plans to bolster its strategic initiatives, including:

• - Accelerating the introduction of 68Ga-PSMA-11 in Japan.
• - Commercializing the radioactive wastewater treatment system and supporting its implementation nationwide.
• - Research and development of new radioisotope therapies based on astatine-211.
• - Strengthening the recruitment of engineers, regulatory affairs professionals, and business developers.

Through these initiatives, AMS aims to expedite the practical application of nuclear theranostics, ultimately striving to provide innovative healthcare solutions to more patients.

Comments from Leadership

Yuuichirou Sugawara, CEO of AMS Planning, expressed his gratitude for the support from Vision Incubate, known for its deep expertise in nuclear medicine. He highlighted the partnership with Mirai Sozo Investments, emphasizing the historical significance this funding round holds for the company's ambitions. Sugawara acknowledged Japan's strict regulations on nuclear medicine but sees them as a potential avenue to create unprecedented innovation. He noted that their collaborative development of a radionuclide adsorption system, "BSL-177," symbolizes their commitment to significant international expansion opportunities.

Messages from Investors

Mirai Sozo Investments - President Yuuki Okada shared enthusiasm about being part of both seed and pre-Series A funding rounds for AMS Planning. He highlighted the strong collaboration between AMS and several major hospitals in Japan, affirming the importance and necessity of AMS’s business concepts in the country’s nuclear medicine landscape.

Vision Incubate - President Kunio Matsumoto expressed excitement about investing in AMS Planning, noting the synergy with Kanazawa University and the potential societal impacts of AMS's unique technology. Matsumoto emphasized that their shared expertise and networks would be fully utilized to support AMS in making meaningful contributions to nuclear medicine within the healthcare sector.

Company Profile

• - Company Name: AMS Planning, Inc.
• - Location: 5-6-9 Shirokanedai, Minato, Tokyo, Room 303
• - CEO: Yuuichirou Sugawara
• - Established: February 7, 2019
• - Business Focus: Development and provision of theranostics technology based on nuclear medicine
• - Website: AMS Planning